Tacrine

Tacrine

SCHEMBL29681895

Nc1c2c(nc3ccccc13)CCCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBCHE

The experimentally established mechanism targets of Tacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 16/20 1.00
BCHE known ✓ P06276 8/20 1.00
TSHR P16473 3/20 1.00
HSD17B10 Q99714 3/20 1.00
ALDH1A1 P00352 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2D6 P10635 2/20 1.00
CHRM1 P11229 2/20 1.00
KDM4E B2RXH2 1/20 1.00
CACNB4 O00305 1/20 1.00
CACNA1A O00555 1/20 1.00
SLC22A2 O15244 1/20 1.00
SLC22A1 O15245 1/20 1.00
ABCC4 O15439 1/20 1.00
CACNA1G O43497 1/20 1.00
CACNG3 O60359 1/20 1.00
CACNA1F O60840 1/20 1.00
CACNA1H O95180 1/20 1.00
APP P05067 1/20 1.00
FABP1 P07148 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tacrine SCHEMBL7714835 1.00 ACHE (1.00) ACHEBCHETSHRHSD17B10ALDH1A1
Tacrine SCHEMBL29594645 1.00 ACHE (1.00) ACHEBCHETSHRHSD17B10ALDH1A1
Tacrine SCHEMBL2828 1.00 ACHE (1.00) ACHEBCHETSHRHSD17B10ALDH1A1
Tacrine SCHEMBL9407893 0.98 CYP1A2 (0.97) ACHEBCHETSHRHSD17B10ALDH1A1
Tacrine SCHEMBL8000475 0.98 ACHE (0.97) ACHEBCHETSHRHSD17B10ALDH1A1
Tacrine SCHEMBL7638777 0.98 ACHE (1.00) ACHEBCHETSHRHSD17B10ALDH1A1
SCHEMBL12043403 0.98 ACHE (1.00) ACHEBCHETSHRHSD17B10ALDH1A1
Tacrine SCHEMBL3270 0.98 ACHE (1.00) ACHEBCHETSHRHSD17B10ALDH1A1
Tacrine SCHEMBL14236722 0.98 ACHE (0.97) ACHEBCHETSHRHSD17B10ALDH1A1
Tacrine SCHEMBL1044163 0.98 ACHE (1.00) ACHEBCHETSHRHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116102495-B 1,2,3, 4-Tetrahydro-9-aminoacridine compound and application thereof 浙江工业大学 2025-03-21 CN claimed
CN-116102495-A 1,2,3, 4-tetrahydro-9-aminoacridine compound and application thereof 浙江工业大学 2023-05-12 CN claimed
CN-116102495-B 1,2,3, 4-Tetrahydro-9-aminoacridine compound and application thereof 浙江工业大学 2025-03-21 CN disclosed
CN-116102495-B 1,2,3, 4-Tetrahydro-9-aminoacridine compound and application thereof 浙江工业大学 2025-03-21 CN disclosed
CN-116102495-B 1,2,3, 4-Tetrahydro-9-aminoacridine compound and application thereof 浙江工业大学 2025-03-21 CN disclosed
US-12247246-B2 Identification of inhibitors of TcpC and TIR NADase activity WASHINGTON UNIVERSITY (US) 2025-03-11 US disclosed
EP-4440621-A1 PEPTIDE-DRUG CONJUGATES FOR TREATMENT OF NEURODEGENERATIVE DISEASES Københavns Universitet (DK) 2024-10-09 EP disclosed
CN-118510545-A Peptide-drug conjugates for the treatment of neurodegenerative diseases 哥本哈根大学 2024-08-16 CN disclosed
CN-113603684-B 1,2, 4-oxadiazole Nrf2 activator-tac Lin Pinge product and preparation method and application thereof 中国药科大学 2023-12-19 CN disclosed
US-20230272449-A1 IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY WASHINGTON UNIVERSITY 2023-08-31 US disclosed
WO-2023127600-A1 DRUG FOR TREATING SITH-1-ASSOCIATED DISEASES 株式会社ウイルス医科学研究所 2023-07-06 WO disclosed
WO-2023099723-A1 PEPTIDE-DRUG CONJUGATES FOR TREATMENT OF NEURODEGENERATIVE DISEASES Københavns Universitet (DK) 2023-06-08 WO disclosed
CN-116102495-A 1,2,3, 4-tetrahydro-9-aminoacridine compound and application thereof 浙江工业大学 2023-05-12 CN disclosed
CN-116102495-A 1,2,3, 4-tetrahydro-9-aminoacridine compound and application thereof 浙江工业大学 2023-05-12 CN disclosed
CN-116102495-A 1,2,3, 4-tetrahydro-9-aminoacridine compound and application thereof 浙江工业大学 2023-05-12 CN disclosed
CN-114588180-B Application of gallnut ethanol extract and fraxinin in preparation of medicine for treating attention deficit hyperactivity disorder 金相希 2023-04-28 CN disclosed
CN-113194972-B Application of gallnut ethanol extract and aesculin in preparation of medicine for improving cognitive ability and preventing or treating dementia 金相希 2022-09-16 CN disclosed
CN-114588180-A Composition for preventing or treating attention deficit hyperactivity disorder 金相希 2022-06-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230272449-A1 IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY NADK, NAPRT, TIPARP ACHE 3265/4885BCHE 2678/4885TSHR 2861/4885
US-12247246-B2 Identification of inhibitors of TcpC and TIR NADase activity NADK, NAPRT, TIPARP ACHE 3265/4885BCHE 2678/4885TSHR 2861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.